JPWO2023194525A5 - - Google Patents

Info

Publication number
JPWO2023194525A5
JPWO2023194525A5 JP2024559036A JP2024559036A JPWO2023194525A5 JP WO2023194525 A5 JPWO2023194525 A5 JP WO2023194525A5 JP 2024559036 A JP2024559036 A JP 2024559036A JP 2024559036 A JP2024559036 A JP 2024559036A JP WO2023194525 A5 JPWO2023194525 A5 JP WO2023194525A5
Authority
JP
Japan
Prior art keywords
prostate cancer
azd5305
metastatic
pharmaceutical product
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511403A (ja
JP2025511403A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/059123 external-priority patent/WO2023194525A1/en
Publication of JP2025511403A publication Critical patent/JP2025511403A/ja
Publication of JP2025511403A5 publication Critical patent/JP2025511403A5/ja
Publication of JPWO2023194525A5 publication Critical patent/JPWO2023194525A5/ja
Pending legal-status Critical Current

Links

JP2024559036A 2022-04-07 2023-04-06 癌を治療するための併用療法 Pending JP2025511403A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362614P 2022-04-07 2022-04-07
US63/362,614 2022-04-07
PCT/EP2023/059123 WO2023194525A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (3)

Publication Number Publication Date
JP2025511403A JP2025511403A (ja) 2025-04-15
JP2025511403A5 JP2025511403A5 (https=) 2026-04-10
JPWO2023194525A5 true JPWO2023194525A5 (https=) 2026-04-10

Family

ID=86184958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559036A Pending JP2025511403A (ja) 2022-04-07 2023-04-06 癌を治療するための併用療法

Country Status (11)

Country Link
US (1) US20250228847A1 (https=)
EP (1) EP4504147A1 (https=)
JP (1) JP2025511403A (https=)
KR (1) KR20240170958A (https=)
CN (1) CN118973555A (https=)
AU (1) AU2023250030A1 (https=)
CA (1) CA3254950A1 (https=)
IL (1) IL316019A (https=)
MX (1) MX2024012369A (https=)
TW (1) TW202404592A (https=)
WO (1) WO2023194525A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
WO2018191141A1 (en) * 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Similar Documents

Publication Publication Date Title
JP2024015120A5 (https=)
JP2022180461A5 (https=)
JP2023041862A5 (https=)
JP5890780B2 (ja) 中枢を介する悪心および嘔吐を治療するための組成物および方法
CN106456626B (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
JP2020516646A5 (https=)
CN107872975A (zh) 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合
IL320452A (en) Combination therapy for prostate cancer
US7705049B2 (en) Methods for treating non-melanoma cancers with PABA
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
TW202539655A (zh) Glp-1受體非肽促效劑化合物之口服投藥
JP2004525143A5 (https=)
JP2016505050A5 (https=)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2010504307A5 (https=)
JP2022177119A5 (https=)
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
CA2721728A1 (en) Treatment of inflammatory bowel disease with 6-mercaptopurine
JPWO2023194525A5 (https=)
JPWO2023194530A5 (https=)
JPWO2023194528A5 (https=)
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途